Health Care·Biotechnology·$2.2B
TYRA Biosciences Inc is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, its work is critical as it aims to address unmet medical needs in oncology, a field that is rapidly evolving with new technologies and treatments.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue figures are not available, any indication of growth would signal the company's market traction and demand for its therapies.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
+8.22%
Avg Stock Reaction
-0.52%
In the last quarter, TYRA reported an EPS of -$0.57, slightly missing expectations. The stock reacted negatively, reflecting investor concerns about its financial performance.
Management Promises & Guidance
Investors are cautious ahead of the earnings report, given the company's recent performance and lack of guidance. The market is looking for any signs of improvement in EPS and revenue.
Bull Case
If TYRA can demonstrate better-than-expected EPS and show signs of revenue growth, it could boost investor confidence and drive the stock price higher.
Bear Case
Conversely, if the company fails to meet expectations again, it could lead to further declines in stock price and increased skepticism about its future prospects.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue figures are not available, any indication of growth would signal the company's market traction and demand for its therapies.
The print will turn on these two things.
Q1
What is the updated EPS figure for this quarter?
Given the company's recent performance, a better-than-expected EPS could indicate a turnaround and improve investor sentiment.
Q2
Is there any indication of revenue growth or new partnerships?
Revenue growth is critical for TYRA's future, and any new partnerships could signal increased market confidence and potential for future success.
Why consensus could be wrong
The Street may underestimate the potential for a turnaround in TYRA's performance, as recent developments in its pipeline could lead to stronger-than-expected results.
Supporting Evidence
The options market is pricing a significant move, indicating that investors expect volatility and potential surprises.
Historical performance shows that the company has a 63% chance of holding or extending its moves after earnings.
Key Risk
If the EPS comes in better than -$0.40, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it will determine investor confidence in TYRA's ability to execute its business strategy.
Bull Confirmed If
An EPS improvement to -$0.40 or better would confirm the bull case.
Bear Confirmed If
An EPS of -$0.60 or worse would confirm the bear case.
Implied Move
±11.56%
Historical Avg
±3.1%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±11.6% while TYRA has averaged ±3.1% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 10 of 27 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 17 of 27 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.8% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If TYRA beats expectations, history suggests a potential stock increase of around 3.1%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.
Miss
A miss could lead to a decline of approximately 1.1%, reflecting ongoing concerns about the company's trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026